Mostrar el registro sencillo

dc.contributor.authorTognin, Stefania
dc.contributor.authorHell, Hendrika H. van
dc.contributor.authorMerritt, Kate
dc.contributor.authorWinter-van Rossum, Inge
dc.contributor.authorBossong, Matthijs G.
dc.contributor.authorKempton, Matthew J.
dc.contributor.authorModinos, Gemma
dc.contributor.authorFusar-Poli, Paolo
dc.contributor.authorMechelli, Andrea
dc.contributor.authorDazzan, Paola
dc.contributor.authorMaat, Arija
dc.contributor.authorDe Haan, Lieuwe
dc.contributor.authorCrespo Facorro, Benedicto 
dc.contributor.authorGlenthoj, Birte
dc.contributor.authorLawrie, Stephen M.
dc.contributor.authorMcDonald, Colm
dc.contributor.authorGruber, Oliver
dc.contributor.authorAmelsvoort, Therese van
dc.contributor.authorArango, Celso
dc.contributor.authorKircher, Tilo
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-03-04T14:02:45Z
dc.date.available2024-03-04T14:02:45Z
dc.date.issued2020
dc.identifier.issn0586-7614
dc.identifier.issn1745-1701
dc.identifier.urihttps://hdl.handle.net/10902/32069
dc.description.abstractIn the last 2 decades, several neuroimaging studies investigated brain abnormalities associated with the early stages of psychosis in the hope that these could aid the prediction of onset and clinical outcome. Despite advancements in the field, neuroimaging has yet to deliver. This is in part explained by the use of univariate analytical techniques, small samples and lack of statistical power, lack of external validation of potential biomarkers, and lack of integration of nonimaging measures (eg, genetic, clinical, cognitive data). PSYSCAN is an international, longitudinal, multicenter study on the early stages of psychosis which uses machine learning techniques to analyze imaging, clinical, cognitive, and biological data with the aim of facilitating the prediction of psychosis onset and outcome. In this article, we provide an overview of the PSYSCAN protocol and we discuss benefits and methodological challenges of large multicenter studies that employ neuroimaging measures.es_ES
dc.description.sponsorshipThe PSYSCAN Project is supported by grant agreement no. 603196 under the European Union’s Seventh Framework Programme. We would like to thank all participants who took part in the study. Conflict of Interest: S.G. received honoraria, advisory board, or consulting fees from the following companies: Gedeon-Richter, Janssen Pharmaceuticals, Janssen-Cilag Polska Sp. z o.o, Otsuka, Pierre Fabre and Sunovion Pharmarmaceuticals. B.G. is the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. Her group has also received a research grant from Lundbeck A/S for another independent investigator initiated study. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. G.S. is president of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry, which is partially financed by the support from pharmaceutical companies. G.S. received consulting fees and/or honoraria for speeches within the last 3 years from Angelini, AOP Orphan, Alkermes, Janssen, Lundbeck, Pfizer. PFP received advisory board fees and research funds from Lundbeck.es_ES
dc.format.extent10 p.es_ES
dc.language.isoenges_ES
dc.publisherOxford University Presses_ES
dc.rightsAttribution 4.0 International. © The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceSchizophrenia Bulletin, 2020, 46(2), 432-441es_ES
dc.subject.otherPsychosises_ES
dc.subject.otherFirst episode of psychosises_ES
dc.subject.otherClinical high risk of psychosises_ES
dc.subject.otherPSYSCANes_ES
dc.subject.otherNeuroimaginges_ES
dc.subject.otherMRIes_ES
dc.subject.otherMachine learninges_ES
dc.subject.otherPredictiones_ES
dc.titleTowards precision medicine in psychosis: Benefits and challenges of multimodal multicenter studies - PSYSCAN: translating neuroimaging findings from research into clinical practicees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1093/schbul/sbz067es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1093/schbul/sbz067
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 International. © The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International. © The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.